Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

By June 29th, the FDA is required to launch a pilot program to “increase unannounced foreign inspections” of facilities that manufacture, package, prepare, compound, label, or process a drug or device that is imported or offered for import into the United States. This mandate includes foreign companies whose products are sent to one or more other foreign establishments prior to importation into the U.S.  

The provisions for the pilot program and the inclusion of companies that do not export directly to the U.S. are set out in the Food and Drug Omnibus Reform Act (FDORA) - contained in the Consolidated Appropriations Act of 2023 - signed by President Biden on December 29, 2022. FDORA requires the pilot program to be launched within 180 days of the Act’s signing date, which puts it squarely on the calendar for June 29, 2023.  

The phrase “increase unannounced foreign inspections” sounds significant, yet the goal of this $10 million program is to gather and compare information from announced and unannounced inspections and then to issue a report with the FDA’s findings and recommendations. So, get ready for this! 

There has long been concern that the FDA’s practice of conducting unannounced inspections of U.S. facilities versus announced-well-in-advance inspections of foreign facilities was producing uneven results, with the specter that the announced-in-advance foreign inspections were not effective. In December 2021, Congress directed the agency to conduct unannounced inspections in India and China in FY2022. 

In December 2022, as noted above, Congress has directed the agency to determine whether, and how, announced and unannounced inspections differ in terms of the number and types of violations, as well as whether barriers exist to conducting unannounced inspections in foreign countries. I think it goes without saying what the results will be. Right?? 

It will take some time for the results to come in, but one thing is for certain: the FDA is squarely focused on conducting unannounced foreign inspections. During our years of inspection preparedness and remediation work with clients, our Quality Executive Partners experts have put a significant effort into supporting and teaching companies to sustain quality and organizational changes. The results have been “crystal clear” time and time again: it is achievable to get your quality operations in tight compliance while at the same time continuing commercial operations at a steady pace. To do so, you need to change the mindset at the leadership level and for that to permeate to those doing the work. As attitude reflects leadership, so does following their lead. Gambling that you can wait to do the right things in quality and manufacturing until you hear about an upcoming inspection is no longer an option. The time for quality is now, and it always will be. 


QxP Founder and CEO Crystal Mersh’s career in pharma quality has spanned three decades and huge companies. Prior to founding QxP in 2012, Crystal has worked in leadership roles at Mylan, Novartis, Watson Pharmaceuticals, and Sanofi.

For more on the subject of quality in pharmaceutical manufacturing, read Crystal’s recent Pharmaceutical Online article,“Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing.” You also might want to check out Crystal’s blog about why “Controls Aren’t Enough.”

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023